Genus-Metabolites Panel as a Novel Diagnostic Tool for Early Metabolic Syndrome in SCZ
August 26, 2024 / Metabolic Syndrome / Biomarkers / Schizophrenia
A study identified a genus-metabolites panel as a promising diagnostic tool for early detection of metabolic syndrome in schizophrenia patients on antipsychotics. This panel, involving specific bacterial and lipid markers, shows high accuracy in predicting metabolic syndrome.
Clinical Management of Metabolic Syndrome Among the Population Attending Geriatric Outpatient Clinics in Qatar
August 26, 2024 / Metabolic Syndrome / Diabetes / Hypertension / Obesity
A study in Qatar found that 97% of elderly patients in geriatric clinics had metabolic syndrome, with high rates of diabetes, hypertension, and obesity. Common treatments included amlodipine, metformin, and rosuvastatin. Early identification and exercise programs could help manage risks.
Good sleep habits important for overweight adults, study suggests
August 23, 2024 / Overweight / Sleep Habits / Obesity / Cardiometabolic Health
New research from Oregon Health & Science University highlights that ignoring sleep signals in overweight adults can lead to adverse health outcomes, including increased belly fat and triglycerides in men and higher body fat and glucose levels in women.
Weight Loss Drugs: A New Perspective on Metabolic Activity
August 23, 2024 / Ozempic / Weight Loss / GLP-1 / Metabolic Activity
A study led by Professor Donal O’Shea challenges the belief that weight loss drugs like Ozempic work solely by reducing appetite. Findings show these medications also increase metabolic activity, significantly contributing to weight loss, especially in individuals with lower baseline metabolic rates.
NLRP3 inflammasome pathway involved in the pathogenesis of metabolic associated fatty liver disease
August 23, 2024 / MAFLD / Liver Disease / Hepatic Fibrosis / Biomarkers
A study finds that increased expression of the NLRP3 inflammasome pathway and IL-1β genes are linked to metabolic-associated fatty liver disease (MAFLD) progression, suggesting they could serve as biomarkers for early detection of hepatic fibrosis in MAFLD patients.
Ozempic Works Differently Than Previously Thought, Study Reveals
August 23, 2024 / Ozempic / GLP-1 / Weight Loss / Metabolism Impact
New research shows that weight loss drugs like Ozempic increase metabolic activity, not just appetite suppression, leading to significant weight loss. This discovery suggests a more complex mechanism behind GLP-1 analogs, emphasizing the need for further research.
Gut microbiome plays a key role in managing type 2 diabetes
August 23, 2024 / Diabetes Management / Type 2 Diabetes / Microbiome
A recent review highlights the gut microbiome’s role in type 2 diabetes development and management, suggesting that targeting the microbiome through probiotics, prebiotics, and personalized therapies could improve outcomes. More research is needed to understand these interactions fully.
Metabolic Risk Factors Contribute to Diabetic Macular Edema Development
August 23, 2024 / Blood Pressure / Metabolic Syndrome / Diabetic Macular Edema
A recent study found that high HbA1c levels, elevated systolic blood pressure, and Black race are linked to an increased risk of diabetic macular edema (DME) in diabetes patients. In contrast, obesity and dyslipidemia showed no significant impact on DME risk.
New 3D imaging tool offers accurate assessment of metabolic health
August 22, 2024 / 3D Imaging / AI / Metabolic Health / Mayo Clinic / Metabolic Syndrome
Mayo Clinic researchers have developed a new AI-driven 3D imaging tool to more accurately assess metabolic syndrome risk and severity, providing a better alternative to traditional measures like BMI. This tool could improve screening for heart disease, diabetes, and other conditions.
Clinical trial in Ireland challenges beliefs about Ozempic and similar new obesity treatments
August 22, 2024 / Ozempic / GLP-1 / Weight Loss / Clinical Trials / Obesity
A clinical trial in Dublin reveals that weight-loss drugs like Ozempic and Wegovy increase metabolic activity, not just satiety, challenging the belief that they simply reduce food intake. This suggests a more complex mechanism behind obesity treatments.
Americans with Type 2 diabetes increased nearly 20% in 10-year period
August 22, 2024 / Type 2 Diabetes / Obesity / Age
Type 2 diabetes prevalence in the U.S. increased nearly 20% from 2012 to 2022, driven by factors such as age, obesity, lack of exercise, and socioeconomic disparities. The highest increases were seen among seniors, Black Americans, and residents of the South and Midwest.
MASH Therapy Pipeline Growing, With a Mix of Results
August 22, 2024 / MASH / FDA Approval / Metabolic Dysfunction
The metabolic dysfunction–associated steatohepatitis (MASH) therapy pipeline is expanding, with mixed results. While obeticholic acid was rejected due to safety concerns, resmetirom has received FDA accelerated approval, marking a positive step forward in MASH treatment.
Macrophage mix helps determine rate and fate of fatty liver disease, study finds
August 22, 2024 / TREM2 / MASH / Fibrosis Therapy / Liver Health
A study reveals that specific macrophage subpopulations expressing TREM2 play a crucial role in resolving metabolic dysfunction-associated steatohepatitis (MASH). The presence of TREM2+ macrophages can slow disease progression, highlighting potential therapeutic targets for treating MASH and liver fibrosis.
Interlinked Pathways: Exploring the Bidirectional Impacts of Periodontitis and Metabolic Syndrome
August 22, 2024 / Periodontitis / Metabolic Syndrome / Oral Health / Chronic Inflammation Diabetes
This review explores the bidirectional relationship between metabolic syndrome (MBS) and periodontitis, highlighting how shared inflammatory pathways and cytokines exacerbate both conditions. The interplay between MBS components, such as obesity and dyslipidemia, and periodontitis contributes to systemic inflammation and increased risk of cardiovascular disease and diabetes.
ADA and Abbott join forces to address nutritional needs in diabetes and obesity
August 21, 2024 / ADA Abbott / Diabetes Management / Obesity / Metabolic Health / Nutrition
The American Diabetes Association and Abbott are collaborating to understand the nutritional needs of people with diabetes, obesity, and metabolic dysfunction. Abbott will provide $1.6 million for research, aiming to improve health outcomes through targeted nutrition formulas and education.
How persistent organic pollutants affect gut health: findings on metabolic disruptions and microbiota changes
August 20, 2024 / Gut Microbiome / Type 2 Diabetes / Diabetes Management
The gut microbiome significantly influences type 2 diabetes development and management. Emerging research suggests that microbiome-targeted therapies, including probiotics, prebiotics, and fecal microbial transplantation, could enhance diabetes treatment outcomes. More longitudinal studies are needed for clinical validation.
IFF developing weight management-focused products
August 20, 2024 / IFF / Weight Control / Metabolic Health / Weight Management
IFF is developing weight management-focused products by leveraging expertise in nutrition and metabolic health. Their offerings include protein sources, Flavorfit flavor modulation technologies, and Litesse fiber solutions aimed at enhancing satiety and supporting metabolic health.
Finding the transcriptional basis of diet-induced obesitySystem
August 20, 2024 / Obesity Treatment / Fatty Liver Disease / MASH
Researchers at Northeast Ohio Medical University found that overexpressing the transcription factor FOXA3 reduces obesity and liver inflammation in mice on a Western diet. FOXA3 enhances liver metabolism, reduces triglyceride accumulation, and promotes energy expenditure via TGR5 activation.
Metabolomics links increased heme iron intake to increased insulin-independent type 2 diabetes risk
August 20, 2024 / Type 2 Diabetese / Heme Iron / Metabolomics T2D Study / Insulin
A study published in Nature Metabolism links high dietary heme iron intake, commonly found in red meat, to an increased risk of insulin-independent type 2 diabetes (T2D). Using metabolomics, the study identified oxidative stress and altered metabolic markers as potential mechanisms driving this increased risk.